← boardnext 2027-12-31
CATX
Perspective Therapeuticsdistress 5/10 · elevated risk$2.93-1%today-48% from 52w high
Lead: neuroendocrine tumors
Revenue
pre-revenue
Liquidity
$271M
Runway
2.9 yrs
Shares 1y
+54%
Price & events
+9.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
-0.7%
1W
-2.3%
1M
-35.0%
3M
+8.1%
6M
-32.6%
1Y
-77.4%
2Y
-58.1%
5Y
-45.7%
All
Overview
- Market Cap
- $334.16M
- Enterprise Value
- $281.79M
- Volume
- 74.91K
- 52 Week Range
- $2.05 – $5.65
- Total Shares
- 114.05M
- Float Shares
- 68.30M
- Short %
- 23.80%
- % Held by Insiders
- 10.81%
- % Held by Institutions
- 77.43%
- RVOL
- 0.03x
- Beta
- 1.75
Pipeline stages · 1 programs
[203Pb]VMT-α-NET, [212Pb]VMT-α-NET
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12-31 Estimated 50% readout ~2028-02-14 | Phase 1/2 | [203Pb]VMT01, [212Pb]VMT01, Nivolumab | Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III | — | recruiting |
| 2028-01-31 Estimated 50% readout ~2028-03-16 | Phase 1/2 | [203Pb]Pb-PSV359, [212Pb]Pb-PSV359 | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma | — | recruiting |
| 2029-11-26 Estimated 50% readout ~2030-01-10 | Phase 1/2 | [203Pb]VMT-α-NET, [212Pb]VMT-α-NET | Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma, Meningioma | — | recruiting |
Catalyst news & presentations · 18
- late 2026Guided 55%readoutPhase 1/2VMT-α-NET · Eight patients in Cohort 3 have opportunity for 48-week follow-upSEC 8-K
- late 2026Guided 55%readoutPhase 1/2[212Pb]VMT-α-NET, [212Pb]VMT01, [212Pb]PSV359 · Further clinical data expected for all three programs.SEC 8-K
- late 2026Guided 55%readoutPhase 1/2PSV359 · Nine patients have opportunity for 32-week follow-upSEC 8-K
- late 2026Guided 55%readoutPhase 1/2VMT01 · 10 patients have opportunity for 24-week follow-upSEC 8-K
- 2026-08-12earningsEarningsEarnings releaseyahoo
- mid-2026readoutVMT-α-NET · All 46 patients in Cohort 2 reach 48-week follow-up; analysis to inform patient selection strategy.SEC 8-K
- May 29-June 2, 2026conferencedata presentationsecondary[212Pb]VMT-α-NET, [212Pb]VMT01, [212Pb]PSV359 · Presentation of interim clinical data at the 2026 ASCO Annual Meeting.SEC 8-K
- Wednesday, January 14, 2026 at 2:15 p.m. PTconferencedata presentationsecondaryCorporate presentation at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- January 8-10, 2026conferencedata presentationsecondaryPhase 1/2VMT-α-NET · Poster presentation at 2026 ASCO GI Symposium of updated interim data from Phase 1/2a trial.SEC 8-K
- 2H 2025conferencedata presentationsecondaryPhase 1/2[212Pb]VMT-α-NET · Further clinical updates to be submitted to scientific congressesSEC 8-K
- 2025-06-21fda agreement[212Pb]VMT-α-NET · FDA alignment to open Cohort 3 in ongoing Phase 1/2a trialSEC 8-K
- 2025-06-21fda agreementVMT-α-NET · FDA alignment to open Cohort 3 at 6.0 mCiSEC 8-K
- June 21-24, 2025conferencedata presentationsecondaryPhase 1/2[212Pb]VMT-α-NET · Dosimetry sub-study presented at SNMMI 2025 Annual MeetingSEC 8-K
- May 30, 2025 at 4:09pm CTconferencedata presentationsecondaryPhase 1/2VMT-α-NET · Oral presentation of VMT-α-NET data at 2025 ASCO Annual Meeting.SEC 8-K
- April 29, 2025trial initiationsecondaryPhase 1/2PSV359 · First patient dosed in Phase 1/2a dose-finding trial of [212Pb]PSV359.SEC 8-K
- this calendar yearreadoutPhase 1/2VMT-α-NET · Update on Phase 1/2a study of VMT-α-NET expectedSEC 8-K
- by the end of this yearregulatory submissionFiled (NDA/BLA)PSV359 · Plans to file IND for PSV359 by end of 2024SEC 8-K
- October 10-13, 2024conferencedata presentationsecondaryPhase 1/2VMT01 · Initial results from Phase 1/2a study of [212Pb]VMT01 presented at SMR meetingSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $13 (+341% upside) · 15 analysts
- 2026-05-05WedbushOutperform
- 2026-04-20WedbushOutperform
- 2026-03-23HC Wainwright & Co.Buy
- 2026-03-18WedbushOutperform
- 2026-03-18B. Riley SecuritiesBuy
- 2026-03-18UBSBuy
Competitors — neuroendocrine tumors
Recent news
- 2026-07-20Perspective Therapeutics (CATX) gains 5.3% beneficial holder led by Millennium - Stock Titan
- 2026-07-20Perspective Therapeutics (CATX) Bank of America Global Healthcare Conference 2026 summary - Quartr
- 2026-07-20Perspective Therapeutics (CATX) RBC Capital Markets Global Healthcare Conference 2026 summary - Quartr
- 2026-07-20Perspective Therapeutics (CATX) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
- 2026-07-17Perspective Therapeutics Announces ESMO 2026 Presentation of Updated [212Pb]VMT-α-NET Data in Advanced Neuroendocrine Tumors - Quiver Quantitative
- 2026-07-17Perspective Therapeutics Announces Acceptance of VMT-α-NET - GlobeNewswire
- 2026-07-17Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026 - Yahoo Finance
- 2026-07-17Perspective's cancer-treatment data gets ESMO oral presentation Oct. 23 - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.